Dhanwantri Bioremedies Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 07-07-2024
- Paid Up Capital ₹ 1.82 Cr
as on 07-07-2024
- Company Age 13 YEARS, 2 MONTHS
- Last Filing with ROC 31 Mar 2022
- Revenue 18.09%
FY 2020
- Profit -139.74%
FY 2020
- Ebitda -112.73%
FY 2020
- Net Worth 897.59%
FY 2020
- Total Assets 284.97%
FY 2020
About Dhanwantri Bioremedies
The Corporate was formerly known as Victory Herbals Private Limited. The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.82 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nagendra Deoke and Nitin Devke serve as directors at the Company.
- CIN/LLPIN
U01120MH2011PTC219488
- Company No.
219488
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jul 2011
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Dhanwantri Bioremedies Private Limited offer?
Dhanwantri Bioremedies Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Honey & Sweeteners, Dietary Supplements, Flaxseed Oil Capsule, Herbal Powder, Stevia Powder, Diabetes Medicine, Ayurvedic Powder and Medicinal Herbs, Stevia Sweetener, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Dhanwantri Bioremedies?
Board Members(2)
Financial Performance and Corporate Structure Insights of Dhanwantri Bioremedies.
Dhanwantri Bioremedies Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 18.09% increase. The company also saw a substantial fall in profitability, with a 139.74% decrease in profit. The company's net worth Soared by an impressive increase of 897.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dhanwantri Bioremedies?
In 2020, Dhanwantri Bioremedies had a promoter holding of 99.01% and a public holding of 0.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indian Institute Of Nlp & Alternative Therapy Private Limited
Active
8 years 9 months Nagendra Deoke is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dhanwantri Bioremedies?
Unlock and access historical data on people associated with Dhanwantri Bioremedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Jan 20, 2021, Dhanwantri Bioremedies has raised a total of ₹ 5.86 Cr, with the most recent deal valued at ₹ 4.62 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
